Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-α and ER-β) in human endometrial hyperplasia

Gynecologic Oncology

Volumn 101, Issue 2, 2006, Pages 214-223

  Vereide, Anne Beate ^a   Kaino, Turid ^b   Sager, Georg ^b   Arnes, Marit ^b   Ørbo, Anne ^b  

^a Institute of Clinical Medicine   (Norway)

^b Medical Faculty   (Norway)

Author keywords

Androgen receptors; Down regulation; Endometrial hyperplasia; Estrogen receptors; Progesterone receptors; Progestins

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; RECEPTOR SUBUNIT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; RECEPTOR DENSITY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TISSUE SECTION; TREATMENT DURATION;

ADULT; ENDOMETRIAL HYPERPLASIA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; RECEPTORS, PROGESTERONE; STROMAL CELLS;

EID: 33646409029     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.030     Document Type: Article

References (46)

1. Clarke C.L., and Sutherland R.L. Progestin regulation of cellular proliferation. Endocr. Rev. 11 (1990) 266-301
2. Graham J.D., and Clarke C.L. Physiological action of progesterone in target tissues. Endocr. Rev. 18 (1997) 502-519
3. Rose P.G. Endometrial carcinoma. N. Engl. J. Med. 335 (1996) 640-649
4. Kurman R.J., Kaminski P.F., and Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56 (1985) 403-412
5. Tsai M.J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 (1994) 451-486
6. Conneely O.M., and Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 65 (2000) 571-577
7. Punnonen R., Mattila J., Kuoppala T., and Koivula T. DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma. J. Cancer Res. Clin. Oncol. 119 (1993) 426-429
8. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer 71 (1993) 1467-1470
9. Nilsson C.G., Haukkamaa M., Vierola H., and Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin. Endocrinol. (Oxf.) 17 (1982) 529-536
10. Gal D. Hormonal therapy for lesions of the endometrium. Semin. Oncol. 13 (1986) 33-36
11. Perino A., Quartararo P., Catinella E., Genova G., and Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur. Fertil. 18 (1987) 137-140
12. Scarselli G., Tantini C., Colafranceschi M., Taddei G.L., Bargelli G., Venturini N., et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur. J. Gynaecol. Oncol. 9 (1988) 284-286
13. Ferenczy A., and Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am. J. Obstet. Gynecol. 160 (1989) 126-131
14. Lindahl B., Alm P., Ferno M., and Norgren A. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res. 10 (1990) 725-730
15. Randall T.C., and Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Gynecol. 90 (1997) 434-440
16. Rose G.L., and Edmonds D.K. Levonorgestrel IUS-treatment for endometrial cystic hyperplasia. Gynecology 104 (1997) 614-616 (case reports)
17. Vereide A.B., Arnes M., Straume B., Maltau J.M., and Ørbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol. Oncol. 91 (2003) 526-533
18. Horn L.C., Schnurrbusch U., Bilek K., Hentschel B., and Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int. J. Gynecol. Cancer 14 (2004) 348-353
19. Ørbo A., Baak J.P., Kleivan I., Lysne S., Prytz P.S., Broeckaert M.A., et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J. Clin. Pathol. 53 (2000) 697-703
20. Mutter G.L., Baak J.P., Crum C.P., Richart R.M., Ferenczy A., and Faquin W.C. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J. Pathol. 190 (2000) 462-469
21. Baak J.P., Ørbo A., van Diest P.J., Jiwa M., de B.P., Broeckaert M., et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am. J. Surg. Pathol. 25 (2001) 930-935
22. Baak J.P., Mutter G.L., Robboy S., van Diest P.J., Uyterlinde A.M., Ørbo A., et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 103 (2005) 2304-2312
23. Vereide A.B., Kaino T., Sager G., and Ørbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol. Oncol. (2005)
24. Huang A., Pettigrew N.M., and Watson P.H. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J. Pathol. 180 (1996) 223-227
25. Kurita T., Young P., Brody J.R., Lydon J.P., O'Malley B.W., and Cunha G.R. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 139 (1998) 4708-4713
26. Hsueh A.J., Peck Jr. E.J., and Clark J.H. Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth. Nature 254 (1975) 337-339
27. Hsueh A.J., Peck Jr. E.J., and Clark J.H. Control of uterine estrogen receptor levels by progesterone. Endocrinology 98 (1976) 438-444
28. Tseng L., and Gurpide E. Effects of progestins on estradiol receptor levels in human endometrium. J. Clin. Endocrinol. Metab. 41 (1975) 402-404
29. Read L.D., Greene G.L., and Katzenellenbogen B.S. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol. Endocrinol. 3 (1989) 295-304
30. Alexander I.E., Shine J., and Sutherland R.L. Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells. Mol. Endocrinol. 4 (1990) 821-828
31. Katzenellenbogen B.S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod. 54 (1996) 287-293
32. Bentel J.M., Birrell S.N., Pickering M.A., Holds D.J., Horsfall D.J., and Tilley W.D. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol. Cell. Endocrinol. 154 (1999) 11-20
33. Burton K.A., Henderson T.A., Hillier S.G., Mason J.I., Habib F., Brenner R.M., et al. Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium. Hum. Reprod. 18 (2003) 2610-2617
34. Ito K., Suzuki T., Akahira J., Moriya T., Kaneko C., Utsunomiya H., et al. Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Int. J. Cancer 99 (2002) 652-657
35. Bozdogan O., Atasoy P., Erekul S., Bozdogan N., and Bayram M. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int. J. Gynecol. Pathol. 21 (2002) 375-382
36. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol. 67 (2005) 335-376
37. Horwitz K.B., Wei L.L., Sedlacek S.M., and d'Arville C.N. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog. Horm. Res. 41 (1985) 249-316
38. Lange C.A., Richer J.K., Shen T., and Horwitz K.B. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J. Biol. Chem. 273 (1998) 31308-31316
39. Lange C.A. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word?. Mol. Endocrinol. 18 (2004) 269-278
40. Terakawa N., Hayashida M., Shimizu I., Ikegami H., Wakimoto H., Aono T., et al. Growth inhibition by progestins in a human endometrial cancer cell line with estrogen-independent progesterone receptors. Cancer Res. 47 (1987) 1918-1923
41. Bigsby R.M., and Cunha G.R. Progesterone and dexamethasone inhibition of uterine epithelial proliferation in two models of estrogen-independent growth. Am. J. Obst. Gynecol. 158 (1988) 646-650
42. Ørbo A., Jaeger R., and Sager G. Serum modifies the concentration-dependent effects that sex steroids exert on cGMP and cAMP levels, and the growth of human C4-I cells (carcinoma of the uterine cervix). Int. J. Oncol. 5 (1994) 619-625
43. Sager G., Ørbo A., Jaeger R., and Engstrom C. Non-genomic effects of progestins-inhibition of cell growth and increased intracellular levels of cyclic nucleotides. J. Steroid Biochem. Mol. Biol. 84 (2003) 1-8
44. Berthelsen E.L., Endresen P.C., Ørbo A., and Sager G. Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death. Anticancer Res. 24 (2004) 3749-3756
45. Revelli A., Massobrio M., and Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr. Rev. 19 (1998) 3-17
46. Simoncini T., and Genazzani A.R. Non-genomic actions of sex steroid hormones. Eur. J. Endocrinol. 148 (2003) 281-292